TB-500 vs Thymosin Beta-4: Are They the Same Thing?
Here is how these two compounds compare — based on published research, not marketing claims.
TB-500
1050
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Thymosin Beta-4
1038
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
This is the most commonly confused comparison in the peptide world. TB-500 is a synthetic fragment of the full-length Thymosin Beta-4 protein. They share key biological activity but are not identical. Most published research uses the full Thymosin Beta-4 protein, not the TB-500 fragment. Understanding this distinction matters for evaluating evidence.
Key Differences
| Attribute | TB-500 | Thymosin Beta-4 |
|---|---|---|
| Evidence Level | Animal Studies | Animal Studies |
| Category | Thymosin Beta-4 Fragment | Thymic Peptide |
| Human Data | Very limited human data specific to the TB-500 fragment. Most evidence is extrapolated from full Thymosin Beta-4 studies. | Several clinical trials including a Phase II for corneal healing. More human data than TB-500. |
| Safety Profile | Limited safety data specific to the fragment. Inferred from Thymosin Beta-4 research. Not FDA-approved. | More safety data than TB-500. Clinical trials conducted for corneal healing and cardiac repair. Generally well-tolerated in published studies. |
| Key Limitations | Most published research used the full protein, not this fragment. Direct evidence for TB-500 specifically is thin. | Clinical development has been slow. More expensive to produce than TB-500. Some trials did not meet primary endpoints. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
TB-500
Contains the active region (amino acids 17-23) of Thymosin Beta-4. This fragment retains the actin-binding activity responsible for cell migration and wound healing. Easier and cheaper to synthesize than the full protein.
Thymosin Beta-4
A 43-amino acid protein that regulates actin polymerization. Controls cell migration, proliferation, and differentiation during tissue repair. Also reduces inflammation and promotes blood vessel formation.
TB-500 contains the active region of Thymosin Beta-4 and shares its core mechanism — actin regulation for cell migration. The full protein may have additional biological activities from regions not included in the fragment. Whether the fragment captures all of the parent protein's therapeutic potential is not definitively established.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 2,088 indexed studies. Here are the key findings.
Thymosin Beta-4 has more published research and more human clinical trial data. TB-500 has very little data specific to the fragment itself. When TB-500 sellers cite research, they are usually citing Thymosin Beta-4 studies. This is important to understand.
For evidence-based evaluation, Thymosin Beta-4 has the actual published research.
For practical availability, TB-500 is more widely available and cheaper to produce.
If reading research, check whether the study used Thymosin Beta-4 (full protein) or the TB-500 fragment — most used the full protein.
The fragment likely retains the core actin-regulatory activity, but this assumption has not been rigorously validated.
Key Limitations
- •Studies cited for TB-500 usually used the full Thymosin Beta-4 protein.
- •Whether the fragment has identical therapeutic properties to the full protein is assumed, not proven.
- •Neither has achieved FDA approval.
- •Head-to-head comparison of the fragment vs full protein does not exist.
PSI Verdict
SUPPORTED BY EVIDENCE
Thymosin Beta-4 promotes wound healing, cell migration, and anti-inflammatory effects in human clinical trials. TB-500 contains the protein's active region and likely retains its core actin-regulatory properties.
NOT YET ESTABLISHED
That TB-500 has identical therapeutic efficacy to full-length Thymosin Beta-4 is assumed, not demonstrated. Most research cited for TB-500 was conducted with the full protein.
CONFIDENCE LEVEL
Moderate. The biological rationale for TB-500 retaining key activity is sound. But if you are evaluating evidence strictly, most of it applies to Thymosin Beta-4, not the fragment. Know what you are actually reading.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
TB-500
"TB-500 is the best peptide for systemic recovery after surgery"Plausible but unproven
"Stacking TB-500 with BPC-157 covers both local and systemic healing"Plausible but unproven
"It healed my torn rotator cuff without surgery"Anecdotal only
Thymosin Beta-4
"Thymosin Beta-4 is the same thing as TB-500"Partially accurate
"There's an eye drop version in clinical trials"Supported by evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
TB-500
Limited safety data specific to the fragment. Inferred from Thymosin Beta-4 research. Not FDA-approved.
Thymosin Beta-4
More safety data than TB-500. Clinical trials conducted for corneal healing and cardiac repair. Generally well-tolerated in published studies.
Thymosin Beta-4 has more published safety data from actual clinical trials. TB-500's safety profile is inferred. Neither has serious safety concerns in available data.
WHAT THE RESEARCH SUGGESTS
TB-500 is a commercially convenient form of Thymosin Beta-4. The research mostly supports the full protein. Applying full-protein data to the fragment is reasonable but not rigorous.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.